Oravax Medical signs agreement to develop oral COVID-19 vaccine in Mexico
Categories: Hi-Tech
Oravax Medical – a joint venture established by Oramed Pharmaceuticals and Premas Biotech – has signed a strategic collaboration agreement with Genomma Lab Internacional (“Genomma”) through which Genomma would develop and commercialize Oravax’s oral COVID-19 vaccine in Mexico.
The agreement would also drive business development in Latin America. Genomma is a leading pharmaceutical and personal care product company in Latin America with an expanding international presence.
Yigal Arnon advised Oravax Medical, established in 2021 in order to bring an oral COVID-19 vaccine to the market. The transaction was led by partner Daniel Green and associate, Tali Har-Oz.
Read more here.
